Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.

@article{Bassand2003TolerabilityOP,
  title={Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.},
  author={Jean Pierre Bassand and Christian Berthe and Armando Bethencourt and Leonardo Bolognese and Jaroslaw W{\'o}jcik},
  journal={Current medical research and opinion},
  year={2003},
  volume={19 2},
  pages={
          107-13
        }
}
BACKGROUND Nadroparin, a low-molecular-weight heparin (LMWH), is an alternative to unfractionated heparin for the acute management of patients with non-ST elevation acute coronary syndrome (ACS): unstable angina or non-Q-wave myocardial infarction. However, unfractionated heparin can be substituted for LMWH in patients requiring percutaneous coronary interventions (PCIs) for the duration of the procedure. The tolerability of this anti-thrombotic regimen (i.e. unfractionated heparin for the… CONTINUE READING
BETA